MAB9013
抗-冠状病毒组抗原抗体，OC-43核蛋白，克隆542-7D
clone 542-7D, Chemicon®, from mouse
登录 查看组织和合同定价。
选择尺寸
关于此项目
UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
Clone:
542-7D, monoclonal
Species reactivity:
human
Application:
immunofluorescence
Technique(s):
immunofluorescence: suitable
Citations:
42
产品名称
抗-冠状病毒组抗原抗体，OC-43核蛋白，克隆542-7D, clone 542-7D, Chemicon®, from mouse
biological source
mouse
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
542-7D, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunofluorescence: suitable
isotype
IgG
shipped in
wet ice
Quality Level
Application
IFA。 最终工作稀释度必须由最终用户确定。
抗冠状病毒组抗原抗体，OC-43核蛋白，克隆542-7D检测冠状病毒组抗原的水平，&已发布&验证可用于IF。
研究子类别
传染病 - 病毒
传染病 - 病毒
研究类别
传染病
传染病
Biochem/physiol Actions
冠状病毒核蛋白；OC-43株
Disclaimer
除非我们的目录或产品随附的其他公司文件中另有说明，否则我们的产品预期仅用于研究用途，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。
Immunogen
表位：OC-43的核蛋白。
Physical form
形式：纯化
纯化免疫球蛋白。提供在pH 7.4的PBS缓冲液中。含0.1%叠氮化钠和载体蛋白。
Preparation Note
在+4°C下保存长达12个月。 应避免反复冻/融循环。
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
Mario Milani et al.
Antiviral research, 189, 105055-105055 (2021-03-14)
The current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and
Gergely Rona et al.
Cell death and differentiation, 29(2), 285-292 (2021-12-05)
The risk of zoonotic coronavirus spillover into the human population, as highlighted by the SARS-CoV-2 pandemic, demands the development of pan-coronavirus antivirals. The efficacy of existing antiviral ribonucleoside/ribonucleotide analogs, such as remdesivir, is decreased by the viral proofreading exonuclease NSP14-NSP10
Daniel Poston et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73(5), e1208-e1211 (2020-12-04)
Cross-reactive immune responses elicited by seasonal coronaviruses might affect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and disease outcomes. We measured neutralizing activity against SARS-CoV-2 in prepandemic sera from patients with prior polymerase chain reaction scan-confirmed seasonal coronavirus infection.
Kentaro Uemura et al.
iScience, 24(10), 103120-103120 (2021-09-21)
Newly emerging or re-emerging viral infections continue to cause significant morbidity and mortality every year worldwide, resulting in serious effects on both health and the global economy. Despite significant drug discovery research against dengue viruses (DENVs) and severe acute respiratory
Jang-Hoon Choi et al.
PloS one, 15(5), e0232757-e0232757 (2020-05-10)
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory infection and continues to infect humans, thereby contributing to a high mortality rate (34.3% in 2019). In the absence of an available licensed vaccine and antiviral agent, therapeutic human antibodies have
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持